Your browser doesn't support javascript.
In vitro ion channel profile and ex vivo cardiac electrophysiology properties of the R(-) and S(+) enantiomers of hydroxychloroquine.
Ballet, Véronique; Bohme, G Andrees; Brohan, Eric; Boukaiba, Rachid; Chambard, Jean-Marie; Angouillant-Boniface, Odile; Carriot, Thierry; Chantoiseau, Céline; Fouconnier, Sophie; Houtmann, Sylvie; Prévost, Céline; Schombert, Brigitte; Schio, Laurent; Partiseti, Michel.
  • Ballet V; Preclinical Safety Investigative Toxicology, Sanofi-Aventis R&D, Chilly-Mazarin, France.
  • Bohme GA; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, Vitry-sur-Seine, France. Electronic address: andrees.bohme@gmail.com.
  • Brohan E; Early Development, Advanced Preparative Chromatography, Sanofi-Aventis R&D, Vitry-sur-Seine, France.
  • Boukaiba R; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, Vitry-sur-Seine, France.
  • Chambard JM; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, Vitry-sur-Seine, France.
  • Angouillant-Boniface O; Early Development, Advanced Preparative Chromatography, Sanofi-Aventis R&D, Vitry-sur-Seine, France.
  • Carriot T; Preclinical Safety Investigative Toxicology, Sanofi-Aventis R&D, Chilly-Mazarin, France.
  • Chantoiseau C; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, Vitry-sur-Seine, France.
  • Fouconnier S; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, Vitry-sur-Seine, France.
  • Houtmann S; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, Vitry-sur-Seine, France.
  • Prévost C; Early Development, Advanced Preparative Chromatography, Sanofi-Aventis R&D, Vitry-sur-Seine, France.
  • Schombert B; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, Vitry-sur-Seine, France.
  • Schio L; Integrated Drug Discovery, Sanofi-Aventis R&D, Vitry-sur-Seine, France.
  • Partiseti M; High Content Biology, Integrated Drug Discovery, Sanofi-Aventis R&D, Vitry-sur-Seine, France.
Eur J Pharmacol ; 915: 174670, 2022 Jan 15.
Article in English | MEDLINE | ID: covidwho-1549763
ABSTRACT
Hydroxychloroquine (HCQ) is a derivative of the antimalaria drug chloroquine primarily prescribed for autoimmune diseases. Recent attempts to repurpose HCQ in the treatment of corona virus disease 2019 has raised concerns because of its propensity to prolong the QT-segment on the electrocardiogram, an effect associated with increased pro-arrhythmic risk. Since chirality can affect drug pharmacological properties, we have evaluated the functional effects of the R(-) and S(+) enantiomers of HCQ on six ion channels contributing to the cardiac action potential and on electrophysiological parameters of isolated Purkinje fibers. We found that R(-)HCQ and S(+)HCQ block human Kir2.1 and hERG potassium channels in the 1 µM-100 µM range with a 2-4 fold enantiomeric separation. NaV1.5 sodium currents and CaV1.2 calcium currents, as well as KV4.3 and KV7.1 potassium currents remained unaffected at up to 90 µM. In rabbit Purkinje fibers, R(-)HCQ prominently depolarized the membrane resting potential, inducing autogenic activity at 10 µM and 30 µM, while S(+)HCQ primarily increased the action potential duration, inducing occasional early afterdepolarization at these concentrations. These data suggest that both enantiomers of HCQ can alter cardiac tissue electrophysiology at concentrations above their plasmatic levels at therapeutic doses, and that chirality does not substantially influence their arrhythmogenic potential in vitro.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Heart / Hydroxychloroquine / Ion Channels / Antimalarials Type of study: Experimental Studies / Prognostic study Limits: Animals / Humans Language: English Journal: Eur J Pharmacol Year: 2022 Document Type: Article Affiliation country: J.ejphar.2021.174670

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Heart / Hydroxychloroquine / Ion Channels / Antimalarials Type of study: Experimental Studies / Prognostic study Limits: Animals / Humans Language: English Journal: Eur J Pharmacol Year: 2022 Document Type: Article Affiliation country: J.ejphar.2021.174670